ViroPharma ( VPHM) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 0.5%. By the end of trading, ViroPharma fell $2.11 (-9.7%) to $19.64 on heavy volume. Throughout the day, 4.8 million shares of ViroPharma exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in price between $19.12-$20.57 after having opened the day at $19.20 as compared to the previous trading day's close of $21.75. Other company's within the Health Care sector that declined today were: Savient Pharmaceuticals ( SVNT), down 21.5%, BG Medicine ( BGMD), down 16.9%, Herbalife ( HLF), down 15.1%, and Graymark Healthcare ( GRMH), down 14.2%. ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. ViroPharma has a market cap of $1.54 billion and is part of the drugs industry. The company has a P/E ratio of 13.1, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 20.6% year to date as of the close of trading on Monday. Currently there are seven analysts that rate ViroPharma a buy, no analysts rate it a sell, and eight rate it a hold. TheStreet Ratings rates ViroPharma as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.